title: Institute of Medicine, Congress seek solutions to FDA's safety woes through reform, funding.
authors.forename: Joel B
authors.initials: JB
authors.lastname: Finkelstein
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000191:economics; D017277:Drug Approval / Q000191:economics; D015507:Drugs, Investigational / Q000009:adverse effects* / Q000191:economics; D035082:Federal Government; D006801:Humans; D015969:National Academies of Science, Engineering, and Medicine, U.S., Health and Medicine Division; D009369:Neoplasms / Q000188:drug therapy / Q000191:economics; D011358:Product Surveillance, Postmarketing / Q000639:trends; D011640:Public Policy; D012109:Research Support as Topic; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000970:Antineoplastic Agents; D015507:Drugs, Investigational